RCT | Second-line levofloxacin-based quadruple therapy vs. bismuth-based quadruple therapy for Helicobacter pylori eradication

Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

Commentary on Twitter

New research – Liou et al – Second-line levofloxacin-based quadruple therapy vs bismuth-based quadruple therapy for H pylori eradication and long-term changes to the gut #microbiota and antibiotic resistome: an RCThttps://t.co/Aipu3TRyFr#Hpylori #microbiome #AMR @emadelomar pic.twitter.com/aeFMAI3FCj

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 20, 2022